Vertex seeks broader use of CF drug Kalydeco
This article was originally published in Scrip
Perhaps it was the distraction on the eve of a pending US government shutdown, which had Wall Street jittery on 30 September – with the Dow Jones, S&P 500 and Nasdaq all tumbling – but investors appeared to have mixed emotions over Vertex Pharmaceuticals' news it had submitted a supplemental new drug application (sNDA) to the US FDA to expand the labeling of Kalydeco (ivacaftor) as a monotherapy for cystic fibrosis (CF) patients 6 years or older who have at least one non-G551D gating mutation in the CF transmembrane conductance regulator (CFTR) gene.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.